ClinicalTrials.gg
CompletedNCT02132637IMAGINE 8Updated Sep 18, 2019Results posted

A Study to Compare the Effect of a Double Dose of Two Long-acting Insulin Therapies in Participants With Type 2 Diabetes

A Phase 3 interventional study of Insulin Peglispro and Insulin Glargine in Type 2 Diabetes Mellitus, sponsored by Eli Lilly and Company. Completed at 3 sites in 2 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-09-18.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing LY2605541 in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. LY2605541 · Diabetes Mellitus, Type 2.

Enrollment
7th of 10
68 · median 339
Started
2014
with 1 other
Phase 3
7 of 10
none open now
Registered
9th of 10
by date
Lead sponsor
10 of 10
Eli Lilly and Company

Among the 10 studies testing LY2605541 in Diabetes Mellitus, Type 2, this one is the 7th largest by enrollment, is one of 2 that started in 2014, is one of 7 in phase 3, and was the 9th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 10 studies testing LY2605541 in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About LY2605541

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing LY2605541 in Diabetes Mellitus, Type 2 as a file.
02

Study summary

The primary purpose of this study is to compare the effect of a double dose of a study drug known as insulin peglispro to a double dose of insulin glargine in participants who have type 2 diabetes. Participants will be treated with study insulin daily, in two 4-week study periods. Each participant will receive insulin peglispro during one treatment period and insulin glargine during the other treatment period.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have type 2 diabetes mellitus (T2DM), based on the World Health Organization (WHO) classification, for ≥1 year.
  • Use any type of basal insulin (except degludec), including once-or twice-daily human insulin neutral protamine Hagedom (NPH), insulin detemir, or insulin glargine.
  • Have (HbA1c) levels ≤9.0% according to local laboratory testing at screening.
  • Have (BMI) ≤40.0 kilograms/square meter (kg/m\^2).
  • Have been treated with stable doses of insulin for at least 30 days before screening with:

    • Basal insulin with daily doses ±30% of mean during the last 4 weeks.
    • Doses of a basal insulin must be between 0.3 unit/kg/day and 1 unit/kg/day.
  • If on metformin, thiazolidinediones (TZDs), sodium glucose co-transporter 2 (SGLT-2) inhibitors, or dipeptidyl peptidase (DPP4) inhibitors, must be on stable doses for the last 30 days.

Exclusion criteria

Exclusion Criteria:

  • Are using prandial, self-mixed, or premixed insulin. Participants using prandial insulin may be switched to everyday (qd) glargine if investigator judges that the participant will still meet fasting glucose requirements for randomization.
  • Are using insulin pump therapy.
  • Have excessive insulin resistance: Defined as >1.0 unit/kg/day as baseline treatment.
  • If being treated with sulfonylureas (SUs) before screening, then must have SUs washed out between screening and randomization.
  • Use any of these concomitant medications: morphine, codeine, antidiuretics, glucagon-like peptide-1 (GLP-1) receptor agonists (for example, exenatide, exenatide once weekly, lixisenatide or liraglutide), or pramlintide, used concurrently or within 90 days before screening.
  • Have hypoglycemia unawareness, defined as confirmed by laboratory test results or by historical episodes of hypoglycemia \<54 mg/dL (3.0 mmol/L) without symptoms.
  • Have fasting hypertriglyceridemia >400 mg/dL (>4.5 mmol/L) at screening, as determined by the local laboratory.
  • Have had any episode of severe hypoglycemia (defined by requiring assistance due to neurologically disabling hypoglycemia) within 6 months before entry into the study.
  • Have had 2 or more emergency room visits or hospitalizations due to poor glucose control in the past 6 months.
  • Have had a previous episode of ketoacidosis as determined by the investigator (ketone bodies at fasting and without acidosis is acceptable) in the past 6 months.
  • Have history of renal transplantation, are currently receiving renal dialysis, or have estimated (eGFR) \<60 milliliters/minute.
  • Have obvious clinical signs or symptoms of liver disease (excluding nonalcoholic fatty liver disease), acute or chronic hepatitis, nonalcoholic steatohepatitis, or elevated liver enzyme measurements.
  • Have active or untreated , have been in remission from clinically significant malignancy (other than basal cell or squamous cell skin cancer) for less than 5 years, or are at increased risk for developing cancer or a recurrence of cancer in the opinion of the investigator.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    Insulin Peglispro

    Standard dose of insulin peglispro administered subcutaneously (SQ) once daily for 4 weeks in one of two study periods. Double dose of insulin peglispro administered once, SQ on day 3 of the inpatient stay.

    Drug: Insulin Peglispro

  • Experimental
    Insulin Glargine

    Standard dose of insulin glargine administered subcutaneously (SQ) once daily for 4 weeks in one of two study periods. Double dose of insulin glargine administered once, SQ on day 3 of the inpatient stay.

    Drug: Insulin Glargine

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Clinically Significant Hypoglycemia

    The percentage was calculated by dividing the number of participants with clinically significant hypoglycemia events defined as blood glucose \<54 milligrams per deciliter (mg/dL) (3.0 millimole per liter \[mmol/L\]) or symptoms of severe hypoglycemia by the total number of participants analyzed, multiplied by 100.

    Time frame: Predose to 84 Hours Post Double Dose

Secondary outcomes

  1. Percentage of Participants With Clinically Significant Hypoglycemia 12 Hours Post Double Dose

    The percentage was calculated by dividing the number of participants with clinically significant hypoglycemia events defined as blood glucose \<54 mg/dL (3.0 mmol/L) or symptoms of severe hypoglycemia by the total number of participants analyzed, multiplied by 100.

    Time frame: Predose to 12 Hours Post Double Dose

  2. Percentage of Participants With Hypoglycemia

    The percentage was calculated by dividing the number of participants with hypoglycemia events defined as blood glucose ≤70 mg/dL (3.9 mmol/L) by the total number of participants analyzed, multiplied by 100.

    Time frame: Predose to 12 Hours Post Double Dose and 84 Hours Post Double Dose

  3. Nadir Glucose

    Nadir glucose was defined as the lowest blood glucose for a participant with blood glucose ≤70 mg/dL (3.9 mmol/L). Least Squares (LS) means were calculated using a mixed model repeated measures (MMRM) analysis including the following fixed effects: treatment, period, sequence, and baseline basal insulin dose stratification factor.

    Time frame: Predose to 84 Hours Post Double Dose

  4. Time to the Nadir Glucose

    Nadir glucose was defined as the lowest blood glucose for a participant with blood glucose ≤70 mg/dL (3.9 mmol/L). The average time was calculated by dividing the sum of time from double dose to the nadir glucose for participants with blood glucose ≤70 mg/dL (3.9 mmol/L) by the number of participants with blood glucose ≤70 mg/dL (3.9 mmol/L) during the first 84 hours after the double dose.

    Time frame: Predose to 84 Hours Post Double Dose

  5. Duration of Glucose ≤70 mg/dL

    The duration in minutes of each hypoglycemia episode with glucose ≤70 mg/dL (3.9 mmol/L) was calculated from start time to end time. The duration for a participant was the sum of the durations over the multiple hypoglycemia episodes. LS means were calculated using an MMRM analysis including the following fixed effects: treatment, period, sequence, and baseline basal insulin dose stratification factor.

    Time frame: Predose to 84 Hours Post Double Dose

  6. Fasting Blood Glucose

    Fasting blood glucose (FBG) was measured by self-monitored blood glucose. LS means were calculated by MMRM analysis with fixed effects of treatment, dosing day, sequence, period, interaction of treatment and dosing day, baseline basal insulin dose stratification factor, and baseline FBG.

    Time frame: Day 1, Day 2, and Day 3 Following Double Dose

  7. Pharmacodynamics: Three-Hour Postprandial Glucose Area Under the Concentration Time Curve (AUC)

    Glucose AUC within 3 hours after each meal assessed by the AUC of glucose from preprandial to 3 hours postprandial. LS means were calculated using an MMRM analysis including the following fixed effects: treatment, period, sequence, and baseline basal insulin dose stratification factor.

    Time frame: Preprandial to 3 Hours Postprandial during the day following the standard dose

  8. Pharmacodynamics: Three-Hour Postprandial Glucose Area Under the Concentration Time Curve (AUC) Excursion

    Glucose AUC excursion within 3 hours after each meal assessed by the AUC of adjusted glucose (= observed glucose - preprandial glucose) from preprandial to 3 hours postprandial. LS means were calculated using an MMRM analysis including the following fixed effects: treatment, period, sequence, and baseline basal insulin dose stratification factor.

    Time frame: Preprandial to 3 Hours Postprandial during the day following the standard dose

  9. Beta Cell Function

    Beta cell function assessed by the change between pre meal tolerance test and 30 minutes post meal tolerance test in C-peptide corrected insulin/Glucose (ΔC-peptide corrected insulin/ΔGlucose). LS means were calculated using an MMRM analysis including the following fixed effects: treatment, period, sequence, and baseline basal insulin dose stratification factor.

    Time frame: 0-30 minutes during the meal tolerance test on the day following the standard dose

07

Results

Posted Apr 20, 2018

Participant flow

Study Period 1
Participant flow — Study Period 1
MilestoneInsulin Peglispro/Insulin GlargineInsulin Glargine/Insulin Peglispro
Started3434
Received at least one dose of study drug3434
Completed3330
Not completed14
Withdrew: Withdrawal by subject04
Withdrew: Physician decision10
Study Period 2 (Crossover)
Participant flow — Study Period 2 (Crossover)
MilestoneInsulin Peglispro/Insulin GlargineInsulin Glargine/Insulin Peglispro
Started3330
Completed3129
Not completed21
Withdrew: Adverse event01
Withdrew: Physician decision20

Outcome measures

PrimaryPercentage of Participants With Clinically Significant Hypoglycemia

The percentage was calculated by dividing the number of participants with clinically significant hypoglycemia events defined as blood glucose \<54 milligrams per deciliter (mg/dL) (3.0 millimole per liter \[mmol/L\]) or symptoms of severe hypoglycemia by the total number of participants analyzed, multiplied by 100.

Time frame:
Predose to 84 Hours Post Double Dose
Reported as:
Number · percentage of participants
Percentage of Participants With Clinically Significant Hypoglycemia
percentage of participantsInsulin PeglisproInsulin Glargine
Percentage of Participants With Clinically Significant Hypoglycemia6.635.5
SecondaryPercentage of Participants With Clinically Significant Hypoglycemia 12 Hours Post Double Dose

The percentage was calculated by dividing the number of participants with clinically significant hypoglycemia events defined as blood glucose \<54 mg/dL (3.0 mmol/L) or symptoms of severe hypoglycemia by the total number of participants analyzed, multiplied by 100.

Time frame:
Predose to 12 Hours Post Double Dose
Reported as:
Number · percentage of participants
Percentage of Participants With Clinically Significant Hypoglycemia 12 Hours Post Double Dose
percentage of participantsInsulin PeglisproInsulin Glargine
Percentage of Participants With Clinically Significant Hypoglycemia 12 Hours Post Double Dose1.622.6
SecondaryPercentage of Participants With Hypoglycemia

The percentage was calculated by dividing the number of participants with hypoglycemia events defined as blood glucose ≤70 mg/dL (3.9 mmol/L) by the total number of participants analyzed, multiplied by 100.

Time frame:
Predose to 12 Hours Post Double Dose and 84 Hours Post Double Dose
Reported as:
Number · percentage of participants
Percentage of Participants With Hypoglycemia
percentage of participantsInsulin PeglisproInsulin Glargine
12 Hours Post Double Dose19.764.5
84 Hours Post Double Dose42.682.3
SecondaryNadir Glucose

Nadir glucose was defined as the lowest blood glucose for a participant with blood glucose ≤70 mg/dL (3.9 mmol/L). Least Squares (LS) means were calculated using a mixed model repeated measures (MMRM) analysis including the following fixed effects: treatment, period, sequence, and baseline basal insulin dose stratification factor.

Time frame:
Predose to 84 Hours Post Double Dose
Reported as:
Least squares mean · mg/dL
Nadir Glucose
mg/dLInsulin PeglisproInsulin Glargine
Nadir Glucose61.70 ± 1.3655.93 ± 0.97
SecondaryTime to the Nadir Glucose

Nadir glucose was defined as the lowest blood glucose for a participant with blood glucose ≤70 mg/dL (3.9 mmol/L). The average time was calculated by dividing the sum of time from double dose to the nadir glucose for participants with blood glucose ≤70 mg/dL (3.9 mmol/L) by the number of participants with blood glucose ≤70 mg/dL (3.9 mmol/L) during the first 84 hours after the double dose.

Time frame:
Predose to 84 Hours Post Double Dose
Reported as:
Mean · hours
Time to the Nadir Glucose
hoursInsulin PeglisproInsulin Glargine
Time to the Nadir Glucose35.92 ± 26.3728.15 ± 23.46
SecondaryDuration of Glucose ≤70 mg/dL

The duration in minutes of each hypoglycemia episode with glucose ≤70 mg/dL (3.9 mmol/L) was calculated from start time to end time. The duration for a participant was the sum of the durations over the multiple hypoglycemia episodes. LS means were calculated using an MMRM analysis including the following fixed effects: treatment, period, sequence, and baseline basal insulin dose stratification factor.

Time frame:
Predose to 84 Hours Post Double Dose
Reported as:
Least squares mean · Minutes per participant
Duration of Glucose ≤70 mg/dL
Minutes per participantInsulin PeglisproInsulin Glargine
Duration of Glucose ≤70 mg/dL95.28 ± 37.57362.26 ± 37.26
SecondaryFasting Blood Glucose

Fasting blood glucose (FBG) was measured by self-monitored blood glucose. LS means were calculated by MMRM analysis with fixed effects of treatment, dosing day, sequence, period, interaction of treatment and dosing day, baseline basal insulin dose stratification factor, and baseline FBG.

Time frame:
Day 1, Day 2, and Day 3 Following Double Dose
Reported as:
Least squares mean · mg/dL
Fasting Blood Glucose
mg/dLInsulin PeglisproInsulin Glargine
Day 1102.03 ± 2.9085.61 ± 2.87
Day 2100.94 ± 2.9286.16 ± 2.91
Day 3102.18 ± 2.9986.27 ± 3.00
SecondaryPharmacodynamics: Three-Hour Postprandial Glucose Area Under the Concentration Time Curve (AUC)

Glucose AUC within 3 hours after each meal assessed by the AUC of glucose from preprandial to 3 hours postprandial. LS means were calculated using an MMRM analysis including the following fixed effects: treatment, period, sequence, and baseline basal insulin dose stratification factor.

Time frame:
Preprandial to 3 Hours Postprandial during the day following the standard dose
Reported as:
Least squares mean · mg/dL*h
Pharmacodynamics: Three-Hour Postprandial Glucose Area Under the Concentration Time Curve (AUC)
mg/dL*hInsulin PeglisproInsulin Glargine
Breakfast633.50 ± 15.59568.64 ± 15.51
Lunch566.00 ± 19.92568.20 ± 19.84
Dinner564.68 ± 15.95577.46 ± 15.95
SecondaryPharmacodynamics: Three-Hour Postprandial Glucose Area Under the Concentration Time Curve (AUC) Excursion

Glucose AUC excursion within 3 hours after each meal assessed by the AUC of adjusted glucose (= observed glucose - preprandial glucose) from preprandial to 3 hours postprandial. LS means were calculated using an MMRM analysis including the following fixed effects: treatment, period, sequence, and baseline basal insulin dose stratification factor.

Time frame:
Preprandial to 3 Hours Postprandial during the day following the standard dose
Reported as:
Least squares mean · mg/dL*h
Pharmacodynamics: Three-Hour Postprandial Glucose Area Under the Concentration Time Curve (AUC) Excursion
mg/dL*hInsulin PeglisproInsulin Glargine
Breakfast266.33 ± 12.04270.32 ± 11.98
Lunch-2.38 ± 11.4236.92 ± 11.34
Dinner134.40 ± 10.20150.23 ± 10.20
SecondaryBeta Cell Function

Beta cell function assessed by the change between pre meal tolerance test and 30 minutes post meal tolerance test in C-peptide corrected insulin/Glucose (ΔC-peptide corrected insulin/ΔGlucose). LS means were calculated using an MMRM analysis including the following fixed effects: treatment, period, sequence, and baseline basal insulin dose stratification factor.

Time frame:
0-30 minutes during the meal tolerance test on the day following the standard dose
Reported as:
Least squares mean · mmol/L
Beta Cell Function
mmol/LInsulin PeglisproInsulin Glargine
Beta Cell Function88.65 ± 8.43103.62 ± 8.32

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Insulin Peglispro—2/64 (3.1%)31/64 (48.4%)
Insulin Glargine—1/67 (1.5%)26/67 (38.8%)
Most frequent serious events
Most frequent serious events
EventInsulin PeglisproInsulin Glargine
Gastritis erosiveGastrointestinal disorders1/640/67
Otitis mediaInfections and infestations1/641/67
Most frequent other events
Showing 10 of 40
Most frequent other events
EventInsulin PeglisproInsulin Glargine
HeadacheNervous system disorders11/647/67
NasopharyngitisInfections and infestations5/646/67
Back painMusculoskeletal and connective tissue disorders4/644/67
Abdominal painGastrointestinal disorders3/641/67
NauseaGastrointestinal disorders3/640/67
Pain in extremityMusculoskeletal and connective tissue disorders3/641/67
EcchymosisSkin and subcutaneous tissue disorders2/643/67
VertigoEar and labyrinth disorders2/641/67
VomitingGastrointestinal disorders2/640/67
DiarrhoeaGastrointestinal disorders1/642/67

Baseline characteristics

All randomized participants

Age, Continuous
Age, Continuous(years)Insulin Peglispro/Insulin GlargineInsulin Glargine/Insulin PeglisproTotal
Mean57.82 ± 8.0657.74 ± 5.8657.78 ± 6.99
Sex: Female, Male
Sex: Female, Male(Participants)Insulin Peglispro/Insulin GlargineInsulin Glargine/Insulin PeglisproTotal
Female101020
Male242448
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Insulin Peglispro/Insulin GlargineInsulin Glargine/Insulin PeglisproTotal
Hispanic or Latino459
Not Hispanic or Latino302959
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Insulin Peglispro/Insulin GlargineInsulin Glargine/Insulin PeglisproTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander101
Black or African American000
White323466
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Insulin Peglispro/Insulin GlargineInsulin Glargine/Insulin PeglisproTotal
United States5510
Germany292958
08

Study locations

3 sites
  • Profil Institute for Clinical Research Inc
    Chula Vista, California 91911, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mainz, 55116, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Neuss, 41460, Germany
09

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2014, a primary completion of Jul 2015 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2018, 2 years 9 months after primary completion. A results delay was requested in Sep 2015.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2014
First posted
May 7, 2014
Start
May 2014
Primary completionActual
Jul 2015
CompletionActual
Jul 2015
Results delay requested
Sep 3, 2015
Results first posted
Apr 20, 2018
Last update
Sep 18, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02132637
Responsible party
Sponsor
First posted
May 7, 2014
Start date
May 2014
Primary completion
Jul 2015
Completion
Jul 2015
Results posted
Apr 20, 2018
Last update
Sep 18, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9AM - 5PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: LY2605541 · Insulin Glargine

Start the discussion